Version May 2024
| Agent | Formulations available | Body weight (kg) | Dose* | |
| Artemether-lumefantrine¶Δ | Available as combination tablets containing:
| Dose administered orally twice daily for 3 days: | ||
| 5 to <15 | 20 mg plus 120 mg | |||
| 15 to <25 | 40 mg plus 240 mg | |||
| 25 to <35 | 60 mg plus 360 mg | |||
| ≥35 | 80 mg plus 480 mg | |||
| Artesunate-amodiaquine | Available as combination tablets containing:
| Dose administered orally once daily for 3 days: | ||
| 4.5 to <9 | 25 mg plus 67.5 mg | |||
| 9 to <18 | 50 mg plus 135 mg | |||
| 18 to <36 | 100 mg plus 270 mg | |||
| ≥36 | 200 mg plus 540 mg | |||
| Artesunate-mefloquine | Available as combination tablets containing:
| Dose administered orally once daily for 3 days: | ||
| 5 to <9 | 25 mg plus 55 mg | |||
| 9 to <18 | 50 mg plus 110 mg | |||
| 18 to <30 | 100 mg plus 220 mg | |||
| ≥30 | 200 mg plus 440 mg | |||
| Artesunate-sulfadoxine-pyrimethamine§ | Not available as a fixed-dose combination; available as co-packaged scored artesunate tablets (50 mg) and SP tablets (500 mg sulfadoxine and 25 mg pyrimethamine) | Artesunate (orally once daily for 3 days): | SP (single dose orally on day 1): | |
| 5 to <10 | 25 mg | 250 mg plus 12.5 mg | ||
| 10 to <25 | 50 mg | 500 mg plus 25 mg | ||
| 25 to <50 | 100 mg | 1000 mg plus 50 mg | ||
| ≥50 | 200 mg | 1500 mg plus 75 mg | ||
| Dihydroartemisinin-piperaquine¥ | Available as combination tablets containing:
| Dose administered orally once daily for 3 days: | ||
| 5 to <8 | 20 mg plus 160 mg‡ | |||
| 8 to <11 | 30 mg plus 240 mg‡ | |||
| 11 to <17 | 40 mg plus 320 mg‡ | |||
| 17 to <25 | 60 mg plus 480 mg‡ | |||
| 25 to <36 | 80 mg plus 640 mg | |||
| 36 to <60 | 120 mg plus 960 mg | |||
| 60 to <80 | 160 mg plus 1280 mg | |||
| ≥80 | 200 mg plus 1600 mg | |||
| Artesunate-pyronaridine tetraphosphate† | Available as a combination tablet containing:
| Dose administered orally once daily for 3 days: | ||
| ≥5 to <8 | 20 mg plus 60 mg | |||
| 8 to <15 | 40 mg plus 120 mg | |||
| 15 to <20 | 60 mg plus 180 mg (use oral suspension) | |||
| 20 to <24 | 60 mg plus 180 mg (use tablet) | |||
| 24 to <45 | 120 mg plus 360 mg | |||
| 45 to <65 | 180 mg plus 540 mg | |||
| ≥65 | 240 mg plus 720 mg | |||
SP: sulfadoxine-pyrimethamine; DP: dihydroartemisinin plus piperaquine.
* In general, the course of ACT is administered for three days. In areas of artemisinin resistance, a six-day course of treatment is warranted.
¶ An orally disintegrating flavored tablet is available in some areas. Take after a full meal or whole milk. If patient vomits within 30 minutes of taking a dose, he or she should repeat the dose. Ideally, the first two doses should be taken 8 hours apart.
Δ We select an alternative agent for patients >65 kg; the efficacy of artemether-lumefantrine agent may be diminished as body weight increases.
◊ Mefloquine hydrochloride (55 mg) is equivalent to mefloquine base (50 mg); mefloquine hydrochloride (220 mg) is equivalent to mefloquine base (200 mg).
§ Sulfadoxine-pyrimethamine should be avoided in the first weeks of life because it could aggravate neonatal hyperbilirubinemia.
¥ Piperaquine prolongs the QT interval by approximately the same amount as chloroquine but by less than quinine. DP should not be used in patients with congenital QT prolongation or who are on medications that prolong the QT interval. DP may be taken with food but should not be taken with a high-fat meal. ACTs containing piperaquine should not be used for treatment of malaria acquired in the Mekong subregion (including southwestern Vietnam, western Cambodia, and northeastern Thailand), unless combined with mefloquine.
‡ Children weighing <25 kg treated with dihydroartemisinin-piperaquine should receive a minimum of 2.5 mg/kg body weight per day of dihydroartemisinin and 20 mg/kg body weight per day of piperaquine daily for 3 days.
† If the patient vomits within 30 minutes of taking a dose, he or she should repeat the dose. Mix the required number of sachets of oral suspension with 10 mL of water in a small cup until the granules are suspended evenly and administer immediately. Tablets and the oral suspension may be taken with or without food.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
